journal article·2015-11-02Open access

Heparin removal from human plasma using molecular imprinted cryogels

Gözde Baydemir, Adil Denizli

Abstract

In this study, heparin-imprinted poly(hydroxyethyl methacrylate-N-[(3-dimethylamino)-propyl] methacrylamide) cryogel column (HpMIP) was synthesized for removal of Hp from human plasma using molecular imprinting technique. Hp removal studies were performed from both aqueous solution and human plasma. Selectivity studies were performed using fast protein liquid chromatography (FPLC) system. The obtained results showed that the HpMIP column can remove Hp from both aqueous solutions and human plasma samples selectively. Ninety per cent of Hp was removed from 28 U/mL of human plasma samples successfully. Non-imprinted cryogel column (NIP) and plane PHEMA column were also synthesized to compare selectivity and non-specific adsorption properties.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Protein purification and stability · Blood properties and coagulation · Analytical chemistry methods development

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (45)

Show source-provided references
1. 10.1016/j.bej.2009.03.01310.1016/j.bej.2009.03.013 ↗
2. 10.1016/j.bej.2010.06.01010.1016/j.bej.2010.06.010 ↗
3. Arrua RD · J Sep Sci · 2011 · 34 · 1610.1002/jssc.201100197 ↗
4. 10.1021/ie061124910.1021/ie0611249 ↗
5. 10.1016/j.seppur.2011.08.01110.1016/j.seppur.2011.08.011 ↗
6. 10.1002/jssc.20120078410.1002/jssc.201200784 ↗
7. 10.1046/j.1538-7836.2003.00270.x10.1046/j.1538-7836.2003.00270.x ↗
8. Cormack P · Sains Malays · 2013 · 42 · 529
9. 10.1002/app.2618710.1002/app.26187 ↗
10. 10.1002/(SICI)1097-4628(19991017)74:3<655::AID-APP19>3.0.CO;2-N10.1002/(SICI)1097-4628(19991017)74:3<655::AID-APP19>3.0.CO;2-N ↗
11. 10.1016/S1570-0232(02)00132-010.1016/S1570-0232(02)00132-0 ↗
12. 10.1016/0378-4347(95)00144-810.1016/0378-4347(95)00144-8 ↗
13. 10.1002/macp.20090042510.1002/macp.200900425 ↗
14. Engelberg H · Pharmacol Rev · 1984 · 36 · 9110.1016/S0031-6997(25)06786-9 ↗
15. 10.1002/app.3553710.1002/app.35537 ↗
16. 10.1016/S0021-9673(96)00956-910.1016/S0021-9673(96)00956-9 ↗
17. 10.1016/S0956-5663(98)00094-310.1016/S0956-5663(98)00094-3 ↗
18. 10.1016/S0021-9673(99)00764-510.1016/S0021-9673(99)00764-5 ↗
19. 10.1016/j.jchromb.2007.07.01910.1016/j.jchromb.2007.07.019 ↗
20. 10.1016/j.biomaterials.2010.07.00810.1016/j.biomaterials.2010.07.008 ↗
21. Jacques LB · Can Med Assoc J · 1973 · 108 · 1291
22. 10.1161/CIRCULATIONAHA.104.51856310.1161/CIRCULATIONAHA.104.518563 ↗
23. 10.1021/bm800724q10.1021/bm800724q ↗
24. 10.1016/j.jhazmat.2011.07.01710.1016/j.jhazmat.2011.07.017 ↗
25. Komiyama M · 2003
26. 10.2012/jbm.b.3310410.2012/jbm.b.33104 ↗
27. 10.1006/abbi.1995.102510.1006/abbi.1995.1025 ↗
28. 10.1126/science.708956410.1126/science.7089564 ↗
29. 10.1002/1521-3935(200207)203:10/11<1532::AID-MACP1532>3.0.CO;2-C10.1002/1521-3935(200207)203:10/11<1532::AID-MACP1532>3.0.CO;2-C ↗
30. 10.1016/j.ab.2012.12.00710.1016/j.ab.2012.12.007 ↗
31. 10.1007/12_2006_10510.1007/12_2006_105 ↗
32. 10.1023/A:101638690261110.1023/A:1016386902611 ↗
33. 10.1016/j.tibtech.2003.08.00210.1016/j.tibtech.2003.08.002 ↗
34. 10.1002/bit.26040041210.1002/bit.260400412 ↗
35. 10.1016/j.chembiol.2005.05.01310.1016/j.chembiol.2005.05.013 ↗
36. 10.1016/j.medengphy.2006.05.00410.1016/j.medengphy.2006.05.004 ↗
37. 10.1021/ac010568610.1021/ac0105686 ↗
38. 10.1378/chest.126.3_suppl.311S10.1378/chest.126.3_suppl.311S ↗
39. 10.1046/j.1365-2141.2003.04334.x10.1046/j.1365-2141.2003.04334.x ↗
40. 10.1161/01.CIR.0000147537.72829.1B10.1161/01.CIR.0000147537.72829.1B ↗
41. 10.1002/anie.19951812110.1002/anie.199518121 ↗
42. 10.1021/cr980039a10.1021/cr980039a ↗
43. 10.1039/c3tb20139b10.1039/c3tb20139b ↗
44. 10.1039/c3an00909b10.1039/c3an00909b ↗
45. 10.1016/j.apsusc.2004.07.05510.1016/j.apsusc.2004.07.055 ↗